Solid GT Overview

  • Founded
  • 2014
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 3
Employees
  • Latest Deal Type
  • M&A

Solid GT General Information

Description

Developer of a gene therapy platform designed to focus on developing novel, disease-modifying therapeutics for Duchenne muscular dystrophy. The company's gene therapy platform develops disease-modifying therapeutics for duchenne muscular dystrophy through gene therapy and delivers widespread expression of microdystrophin, a much smaller functional version of dystrophin, through robust delivery systems, enabling healthcare industries to implement their gene therapy.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Parent Company
Primary Office
  • One Broadway
  • Cambridge, MA 02142
  • United States
+1 (617) 000-0000
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Solid GT Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 30-Mar-2017 000.00 Completed Generating Revenue
2. Early Stage VC (Series B) 03-Nov-2015 000.00 000.00 Completed Startup
1. Early Stage VC (Series A) $10M $10M Completed Startup
To view Solid GT’s complete valuation and funding history, request access »

Solid GT Executive Team (1)

Name Title Board Seat Contact Info
Ilan Ganot Co-Founder, President, Chief Executive Officer & Board Member
To view Solid GT’s complete executive team members history, request access »

Solid GT Board Members (3)

Name Representing Role Since
Ilan Ganot Self Co-Founder, President, Chief Executive Officer & Board Member 000 0000
To view Solid GT’s complete board members history, request access »

Solid GT Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Solid GT Former Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Biogen Corporation Minority 000 0000 000000 0
Duchenne Children Trust Other Minority 000 0000 000000 0
Duchenne Research Fund Corporation Minority 000 0000 000000 0
Janus Capital Group Other Minority 000 0000 000000 0
Joining Jack Other Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »